Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic &amp; prognostic approaches

Hybar, Habib; Saki, Najmaldin; Maleknia, Mohsen; Moghaddasi, Mana; Bordbar, Armin; Naghavi, Maliheh

doi:10.1007/s11033-021-06240-0

Cited by 2 publications

(2 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This inhibition further exacerbates the imbalance, resulting in a more pronounced inflammatory response. Cysteinyl leukotrienes (LTC4, LTD4 and LTE4) are potent inflammatory mediators crucial in AERD pathogenesis 157 . They cause bronchoconstriction, increased vascular permeability, mucus production and recruitment of inflammatory cells.…”

Section: Mechanisms Of the Most Important Allergic Diseasesmentioning

confidence: 99%

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Jutel,

Agache,

Zemelka‐Wiacek

et al. 2023

Allergy

View full text Add to dashboard Cite

The exponential growth of precision diagnostic tools, including omic technologies, molecular diagnostics, sophisticated genetic and epigenetic editing, imaging and nano‐technologies and patient access to extensive health care, has resulted in vast amounts of unbiased data enabling in‐depth disease characterization. New disease endotypes have been identified for various allergic diseases and triggered the gradual transition from a disease description focused on symptoms to identifying biomarkers and intricate pathogenetic and metabolic pathways. Consequently, the current disease taxonomy has to be revised for better categorization. This European Academy of Allergy and Clinical Immunology Position Paper responds to this challenge and provides a modern nomenclature for allergic diseases, which respects the earlier classifications back to the early 20th century. Hypersensitivity reactions originally described by Gell and Coombs have been extended into nine different types comprising antibody‐ (I‐III), cell‐mediated (IVa‐c), tissue‐driven mechanisms (V‐VI) and direct response to chemicals (VII). Types I‐III are linked to classical and newly described clinical conditions. Type IVa‐c are specified and detailed according to the current understanding of T1, T2 and T3 responses. Types V‐VI involve epithelial barrier defects and metabolic‐induced immune dysregulation, while direct cellular and inflammatory responses to chemicals are covered in type VII. It is notable that several combinations of mixed types may appear in the clinical setting. The clinical relevance of the current approach for allergy practice will be conferred in another article that will follow this year, aiming at showing the relevance in clinical practice where various endotypes can overlap and evolve over the lifetime.

show abstract

Section: Mechanisms Of the Most Important Allergic Diseasesmentioning

confidence: 99%

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Jutel,

Agache,

Zemelka‐Wiacek

et al. 2023

Allergy

View full text Add to dashboard Cite

show abstract

“…Therefore, increased LTE4 generates a pro-inflammatory environment associated with bronchoconstriction, mucus hypersecretion and hypervascularisation. AERD patients present prominent T2 inflammation leading to increased eosinophils in the bronchial and nasosinusal mucosa, overexpression of platelets and increased mast cell degranulation [25]. AERD is a relevant risk factor associated with severe airway disease and treatment failure in CRSwNP and asthma.…”

Section: Aspirin-exacerbated Respiratory Disease: a Diagnostic Challe...mentioning

confidence: 99%

The Utility of Nasal Challenges to Phenotype Asthma Patients

Bentabol‐Ramos

María

Vidal-Diaz

et al. 2022

IJMS

View full text Add to dashboard Cite

Asthma is a heterogeneous disease in terms of both phenotype and response to therapy. Therefore, there is a great need for clinically applicable tools allowing for improved patient classification, and selection for specific management approaches. Some interventions are highly helpful in selected patients (e.g., allergen immunotherapy or aspirin desensitization), but they are costly and/or difficult to implement. Currently available biomarkers measurable in peripheral blood or exhaled air display many limitations for asthma phenotyping and cannot identify properly the specific triggers of the disease (e.g., aeroallergens or NSAID). The united airway concept illustrates the relevant epidemiological and pathophysiological links between the upper and lower airways. This concept has been largely applied to patient management and treatment, but its diagnostic implications have been less often explored. Of note, a recent document by the European Academy of Allergy and Clinical Immunology proposes the use of nasal allergen challenge to confirm the diagnosis of allergic asthma. Similarly, the nasal challenge with lysine acetylsalicylate (L-ASA) can be used to identify aspirin-sensitive asthma patients. In this review, we will summarize the main features of allergic asthma and aspirin-exacerbated respiratory disease and will discuss the methodology of nasal allergen and L-ASA challenges with a focus on their capacity to phenotype the inflammatory disease affecting both the upper and lower airways.

show abstract

Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches

Cited by 2 publications

References 69 publications

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

Nomenclature of allergic diseases and hypersensitivity reactions: Adapted to modern needs: An EAACI position paper

The Utility of Nasal Challenges to Phenotype Asthma Patients

Contact Info

Product

Resources

About